Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy

被引：111

作者：

Greub, G ^{[1
]}

Cozzi-Lepri, A

Ledergerber, B

Staszewski, S

Perrin, L

Miller, V

Francioli, P

Furrer, H

Battegay, M

Vernazza, P

Bernasconi, E

Günthard, HF

Hirschel, B

Phillips, AN

Telenti, A

机构：

[1] Univ Lausanne Hosp, Lausanne, Switzerland

[2] UCL Royal Free & Univ Coll Med Sch, London, England

[3] Univ Zurich Hosp, CH-8091 Zurich, Switzerland

[4] Univ Frankfurt Klinikum, D-6000 Frankfurt, Germany

[5] Univ Hosp Geneva, Geneva, Switzerland

[6] SHCS Data Ctr, Lausanne, Switzerland

[7] Univ Hosp Bern, CH-3010 Bern, Switzerland

[8] Univ Basel Hosp, CH-4031 Basel, Switzerland

[9] Cantonal Hosp, St Gallen, Switzerland

[10] Cantonal Hosp, Lugano, Switzerland

来源：

AIDS | 2002年 / 16卷 / 14期

关键词：

D O I：

10.1097/00002030-200209270-00017

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Low-level viral rebound (LLVR) was identified in 704 of 2055 patients on effective antiretroviral treatment. It was followed by a value of 50 copies/ml, a 'blip', in 490 patients, whereas two consecutive values between 51 and 500 copies/ml, a 'bump', were observed in 155. Hazard ratios of viral failure were 2.01 for blips and 5.80 for bumps. LLVR is frequent and generally resolves spontaneously, but is associated with an increased risk of viral failure.

引用

页码：1967 / 1969

页数：3

共 10 条

[1] Günthard HF, 1999, J VIROL, V73, P9404
[2] Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples
Günthard, HF
Wong, JK
Ignacio, CC
Havlir, DV
Richman, DD
[J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (10) : 869 - 876
[3] Prevalence and predictive value of intermittent viremia with combination HIV therapy
Havlir, DV
Bassett, R
Levitan, D
Gilbert, P
Tebas, P
Collier, AC
Hirsch, MS
Ignacio, C
Condra, J
Günthard, HF
Richman, DD
Wong, JK
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02): : 171 - 179
[4] The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
Kempf, DJ
Rode, RA
Xu, Y
Sun, E
Heath-Chiozzi, ME
Valdes, J
Japour, AJ
Danner, S
Boucher, C
Molla, A
Leonard, JM
[J]. AIDS, 1998, 12 (05) : F9 - F14
[5] Antiretroviral resistance during successful therapy of HIV type 1 infection
Martinez-Picado, J
DePasquale, MP
Kartsonis, N
Hanna, GJ
Wong, J
Finzi, D
Rosenberg, E
Günthard, HF
Sutton, L
Savara, A
Petropoulos, CJ
Hellmann, N
Walker, BD
Richman, DD
Siliciano, R
D'Aquila, RT
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (20) : 10948 - 10953
[6] The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
Ramratnam, B
Mittler, JE
Zhang, LQ
Boden, D
Hurley, A
Fang, F
Macken, CA
Perelson, AS
Markowitz, M
Ho, DD
[J]. NATURE MEDICINE, 2000, 6 (01) : 82 - 85
[7] Detection of low HIV-1 RNA levels in plasma
Schockmel, GA
Yerly, S
Perrin, L
[J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 14 (02): : 179 - 183
[8] Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1
Stanley, SK
Ostrowski, MA
Justement, JS
Gantt, K
Hedayati, S
Mannix, M
Roche, K
Schwartzentruber, DJ
Fox, CH
Fauci, AS
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (19) : 1222 - 1230
[9] Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia
Yerly, S
Kaiser, L
Perneger, TV
Cone, RW
Opravil, M
Chave, JP
Furrer, H
Hirschel, B
Perrin, L
[J]. AIDS, 2000, 14 (03) : 243 - 249
[10] Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
Zhang, LQ
Ramratnam, B
Tenner-Racz, K
He, YX
Vesanen, M
Lewin, S
Talal, A
Racz, P
Perelson, AS
Korber, BT
Markowitz, M
Ho, DD
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) : 1605 - 1613

← 1 →